R&D channel feed

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

2 days ago
China
AI

No­vo Nordisk plans Phase 3 tri­als of oral, in­jectable amy­cretin for ear­ly 2026

2 days ago
Pharma

Ex­clu­sive: Kennedy picks for vac­cine ad­vi­so­ry board were paid ex­perts against Mer­ck in civ­il cas­es

2 days ago
Pharma
FDA+

In­smed aims to raise $750M in one of the largest stock of­fer­ings this year

3 days ago
Financing

Ku­ra, Ky­owa say Phase 1 up­date sup­ports menin in­hibitor com­bos 

3 days ago

Schrödinger says ear­ly MALT1 da­ta could lay 'great foun­da­tion' for com­bos

3 days ago

Ex­clu­sive: Organoid start­up rais­es $21M to test drugs and vac­cines in hu­man lymph nodes-in-a-dish

3 days ago
Startups

House ap­pro­pri­a­tors call for FDA tweaks on ac­cel­er­at­ed ap­provals, biosim­i­lars

3 days ago
FDA+

Watch Post-Hoc Live: What hap­pens when AI thinks in ways we can’t un­der­stand?

3 days ago
Editor's note
AI

Ca­balet­ta Bio shares CAR-T re­sults in three au­toim­mune con­di­tions

4 days ago

Vaxart shares surge on norovirus vac­cine da­ta as it seeks fund­ing for new tri­als

4 days ago

BMS’ Rayze­Bio inks ra­dio­phar­ma deal in prostate can­cer for $350M up­front

4 days ago
Deals

Ar­genx says its drug Vyv­gart looks promis­ing in two more au­toim­mune dis­eases

4 days ago
Pharma

FDA’s Makary says he wasn’t part of de­ci­sion to gut ACIP, de­fers pos­si­ble VRB­PAC changes to Prasad

4 days ago
Pharma
FDA+

FDA places hold on Gilead­'s stud­ies of HIV treat­ment pill com­bo

5 days ago
FDA+

Ex­clu­sive: Re­boot­ing dead hu­man brains, a biotech start­up seeks to rein­vent ear­ly drug test­ing work

5 days ago
In Focus

Up­dat­ed: Mer­ck wins FDA ap­proval for RSV an­ti­body drug, mak­ing a hot mar­ket more com­pet­i­tive

5 days ago
Pharma
FDA+

Fed­er­al­ly-fund­ed can­cer re­search comes to a per­ilous cross­roads

5 days ago
Bioregnum

Mer­ck says its oral PC­SK9 in­hibitor ‘sig­nif­i­cant­ly’ cut cho­les­terol in two Phase 3 tri­als

6 days ago

NewAms­ter­dam's ex­per­i­men­tal cho­les­terol drug re­duces pres­ence of Alzheimer's bio­mark­er

6 days ago

Met­sera shares ear­ly da­ta on an­ti-obe­si­ty amylin can­di­date

6 days ago
Startups

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

Last week

Ot­su­ka spells out Phase 3 win in rare kid­ney dis­ease, Ve­ra’s stock takes a hit

Last week

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

Last week
Pharma
1234 Next page Last page
A service from the Financial Times